The FDA’s Center for Biologics Evaluation and Research (CBER) will convene a virtual meeting of the Vaccines and Related Biological Products Advisory Committee on June 10
Novavax, Inc. (NVAX) announced positive results from the animal study of its combo vaccine for influenza and COVID-19.
The positive news however did little to stem the sell-off in shares that began in late April.
Novavax (NASDAQ: NVAX) shares are trading lower amid reports competing COVID-19 vaccines may be approved in Europe. The stock also dipped on reports the company is unlikely to seek emergency use authorization for its COVID-19 vaccine until June.
Companies Reporting Before The Bell
• Revlon (NYSE:REV) is likely to report earnings for its first quarter.
• Bluegreen Vacations (NYSE:BVH) is expected to report earnings for its first quarter.
Biotech stocks came under pressure in the week ended May 7 as traders digested a slew of earnings news flow and a handful of clinical trial readouts. COVID-19 vaccine stocks came under pressure following the U.S.